Interdisciplinary Development of an Intravenous Infusion Protocol for Orthoclone OKT3

Jacqueline Glee Byrd, Alicia Raulinaitis, Patricia Boswell Burke, Darlene Welsh

Research output: Contribution to journalArticlepeer-review


The development and implementation of an infusion protocol for Orthoclone OKT3 (Ortho Biotech, Inc., Raritan, NJ) is described in this article. OKT3 is a potent immunosuppressant drug used to lower the incidence of graft rejection in transplant patients. Nurses and physicians use the protocol described in this article to administer OKT3 to heart and lung transplant patients at our institution. Pharmacokinetics, along with the nursing care, associated with OKT3 administration are described in the protocol section. The benefits of protocol use are reported in the conclusion.

Original languageEnglish
Pages (from-to)X-XI
JournalJournal of Intravenous Nursing
Issue number3
StatePublished - May 1996

ASJC Scopus subject areas

  • General Nursing
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Interdisciplinary Development of an Intravenous Infusion Protocol for Orthoclone OKT3'. Together they form a unique fingerprint.

Cite this